Mersana Therapeutics Inc (MRSN)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Anna Protopapas
Employees:
170
840 MEMORIAL DRIVE, CAMBRIDGE, MA 02139
617-498-0020

Mersana Therapeutics, Inc. develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for ovarian cancer and NSCLC adenocarcinoma.

Data derived from most recent annual or quarterly report
Market Cap 418.052 Million Shares Outstanding99.774 Million Avg 30-day Volume 1.559 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.61
Price to Revenue10209.6163 Debt to Equity0.2023 EBITDA-168.003 Million
Price to Book Value3.6061 Operating Margin-392693.0233 Enterprise Value285.693 Million
Current Ratio3.975 EPS Growth-0.685 Quick Ratio3.744
1 Yr BETA 1.4103 52-week High/Low 8.34 / 2.68 Profit Margin-395488.3721
Operating Cash Flow Growth-87.4103 Altman Z-Score-1.818 Free Cash Flow to Firm -108.651 Million
Earnings Report2023-05-08
View SEC Filings from MRSN instead.

View recent insider trading info

Mersana Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding MRSN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MRSN

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-12-16 by LOWINGER TIMOTHY B
  • 4: filed on 2022-12-02 by YANG ARVIN
  • 4: filed on 2022-08-18 by MISRA TUSHAR
  • 4: filed on 2022-06-10 by HACK ANDREW A. F.
  • 4: filed on 2022-06-10 by ALLEVA LAWRENCE M
  • 4: filed on 2022-06-10 by DERE WILLARD H
  • 4: filed on 2022-06-10 by DIAZ ALLENE M.
  • 4: filed on 2022-06-10 by MOTT DAVID M
  • 4: filed on 2022-06-10 by HUBER MARTIN H. JR.
  • 4: filed on 2022-06-10 by HEGE KRISTEN

    • Events (8k)

  • 8-K: filed on 2023-03-13:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-01:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-25:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-27:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
  • 8-K: filed on 2022-12-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-06:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    PROTOPAPAS ANNA PRESIDENT & CEO

    • Officer
    • Director
    		 371,611 2023-01-13 1

    CARVAJAL ALEJANDRA SVP, CHIEF LEGAL OFFICER

    • Officer
    		 227,405 2023-01-13 2

    LOWINGER TIMOTHY B SVP, CHIEF SCI.&TECH. OFF.

    • Officer
    		 781,470 2023-01-13 2

    DESCHUYTNER BRIAN SVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 353,605 2023-01-13 1

    MANDELIA ASHISH VP, CONTROLLER

    • Officer
    		 125,083 2023-01-13 1

    YANG ARVIN SVP, CHIEF MEDICAL OFFICER

    • Officer
    		 350,933 2023-01-13 2

    MISRA TUSHAR SVP, CMO

    • Officer
    		 172,525 2023-01-13 2

    MOTT DAVID M

    • Director
    		 45,000 2022-06-09 1

    HEGE KRISTEN

    • Director
    		 45,000 2022-06-09 1

    DERE WILLARD H

    • Director
    		 45,000 2022-06-09 1

    ALLEVA LAWRENCE M

    • Director
    		 45,000 2022-06-09 1

    HUBER MARTIN H. JR.

    • Director
    		 45,000 2022-06-09 1

    HACK ANDREW A. F.

    • Director
    		 45,000 2022-06-09 7

    DIAZ ALLENE M.

    • Director
    		 45,000 2022-06-09 1

    KAUFMAN MICHAEL J. CHIEF MANUFACTURING OFFICER

    • Officer
    		 77,332 2021-07-15 0

    KERINS PATRICK J

    • 10% Owner
    		 No longer subject to file 2020-09-14 0

    SANDELL SCOTT D

    • 10% Owner
    		 No longer subject to file 2020-09-14 0

    BASKETT FOREST

    • 10% Owner
    		 No longer subject to file 2020-09-14 0

    NEW ENTERPRISE ASSOCIATES 14, L.P.

    • 10% Owner
    		 No longer subject to file 2020-09-14 0

    NEA PARTNERS 14, L.P.

    NEA 14 GP, LTD

    • 10% Owner
    		 No longer subject to file 2020-09-14 0

    SONSINI PETER W.

    • 10% Owner
    		 No longer subject to file 2020-09-14 0

    FLORENCE ANTHONY A. JR.

    • 10% Owner
    		 No longer subject to file 2020-09-14 0

    JACK EVA M. CHIEF BUS. OFFICER, TRES, SEC.

    • Officer
    		 0 2020-09-14 0

    HUEBNER DIRK CHIEF MEDICAL OFFICER

    • Officer
    		 0 2020-01-15 0

    NEW ENTERPRISE ASSOCIATES 14, L.P.

    SONSINI PETER W.

    BASKETT FOREST

    FLORENCE ANTHONY A. JR.

    KERINS PATRICK J

    NEA 14 GP, LTD

    NEA PARTNERS 14, L.P.

    SANDELL SCOTT D

    • 10% Owner
    		 11,959,520 2019-08-28 0

    NEW ENTERPRISE ASSOCIATES 14, L.P.

    SONSINI PETER W.

    NEA 14 GP, LTD

    NEA PARTNERS 14, L.P.

    BARRIS PETER J

    BASKETT FOREST

    FLORENCE ANTHONY A. JR.

    KERINS PATRICK J

    SANDELL SCOTT D

    • 10% Owner
    		 11,890,138 2019-03-05 0

    FOSTER WAYNE VICE PRESIDENT OF FINANCE

    • Officer
    		 0 2019-01-23 0

    SPELLMAN DAVID A CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2019-01-23 0

    BERGSTROM DONALD A CHIEF MEDICAL OFFICER

    • Officer
    		 0 2018-02-02 0

    NAYEEM SARA M.

    • Director
    		 0 2018-01-02 0

    FMR LLC

    • SEE REMARK 1
    		 No longer subject to file 2017-07-03 0

    BARRIS PETER J

    • 10% Owner
    		 8,140,138 2017-07-03 0

    BARRETT M JAMES

    • 10% Owner
    		 8,140,138 2017-07-03 0

    VISWANATHAN RAVI

    • 10% Owner
    		 8,140,138 2017-07-03 0

    NEW ENTERPRISE ASSOCIATES 14, L.P.

    NEA PARTNERS 14, L.P.

    NEA 14 GP, LTD

    • 10% Owner
    		 8,140,138 2017-07-03 0

    JONES ELAINE V

    • Director
    		 0 2017-06-27 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    MERSANA THERAPEUTICS INC MRSN 2023-03-24 15:45:03 UTC 4.4119 0.4081 900000
    MERSANA THERAPEUTICS INC MRSN 2023-03-24 15:15:03 UTC 4.4119 0.4081 900000
    MERSANA THERAPEUTICS INC MRSN 2023-03-24 14:45:03 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-24 14:15:03 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-24 13:45:03 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-24 13:15:04 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-24 12:45:03 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-23 22:15:04 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-23 21:45:04 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-23 21:15:04 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-23 20:45:03 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-23 20:15:03 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-23 19:45:03 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-23 19:15:03 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-23 18:45:04 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-23 18:15:03 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-23 17:45:03 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-23 17:15:03 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-23 16:45:04 UTC 4.1619 0.4081 950000
    MERSANA THERAPEUTICS INC MRSN 2023-03-23 16:15:03 UTC 4.1619 0.4081 950000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments